LOAMS
Lombard Odier Asset Management (Switzerland) Portfolio holdings
AUM
$1.98B
This Quarter Return
+8.99%
1 Year Return
+25.93%
3 Year Return
+103.45%
5 Year Return
+160.5%
10 Year Return
+469.02%
AUM
$1.97B
AUM Growth
+$1.97B
(+31%)
Cap. Flow
+$367M
Cap. Flow
% of AUM
18.65%
Top 10 Holdings %
Top 10 Hldgs %
16.48%
Holding
519
New
126
Increased
265
Reduced
66
Closed
19
Top Buys
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$26.2M |
| 2 |
Biogen
BIIB
|
$26.1M |
| 3 |
Ameriprise Financial
AMP
|
$25.1M |
| 4 |
InMode
INMD
|
$23.7M |
| 5 |
BioNTech
BNTX
|
$21M |
Top Sells
| 1 |
Moderna
MRNA
|
$29.5M |
| 2 |
Futu Holdings
FUTU
|
$23.2M |
| 3 |
Intellia Therapeutics
NTLA
|
$20.7M |
| 4 |
Charles Schwab
SCHW
|
$18M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
$10.5M |
Sector Composition
| 1 | Healthcare | 50.36% |
| 2 | Consumer Discretionary | 12.8% |
| 3 | Financials | 9.81% |
| 4 | Technology | 6.13% |
| 5 | Industrials | 3.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Intellia Therapeutics
NTLA
$1.22B
| $25.1M | 1.27% |
155,201
-127,752
| -45% | -$20.7M |
|
27
Voya Financial
VOYA
$7.24B
| $25M | 1.27% |
406,414
-5,050
| -1% | -$311K |
|
28
Apellis Pharmaceuticals
APLS
$3.48B
| $25M | 1.27% |
395,033
+15,638
| +4% | +$988K |
|
29
Brunswick
BC
$4.15B
| $24.9M | 1.26% |
250,000
+20,000
| +9% | +$1.99M |
|
30
Medifast
MED
$154M
| $24.1M | 1.22% |
85,000
+5,000
| +6% | +$1.41M |
|
|
DRNA
31
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $23.7M | 1.2% |
636,011
+109,953
| +21% | +$4.1M |
|
32
Chemed
CHE
$6.67B
| $23.7M | 1.2% |
50,000
| – | – |
|
|
33
InMode
INMD
$944M
| $23.7M | 1.2% |
+250,000
| New | +$23.7M |
|
34
Novavax
NVAX
$1.23B
| $23.2M | 1.18% |
109,423
+43,021
| +65% | +$9.13M |
|
|
35
Charles Schwab
SCHW
$174B
| $22.8M | 1.15% |
312,521
-247,394
| -44% | -$18M |
|
36
Thor Industries
THO
$5.79B
| $22.6M | 1.15% |
200,000
| – | – |
|
37
Teladoc Health
TDOC
$1.35B
| $22.4M | 1.14% |
134,919
+97,470
| +260% | +$16.2M |
|
|
TRHC
38
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $22.2M | 1.13% |
443,743
+99,409
| +29% | +$4.97M |
|
|
NVTA
39
DELISTED
Invitae Corporation
NVTA
| $22.1M | 1.12% |
656,137
+352,541
| +116% | +$11.9M |
|
40
Neurocrine Biosciences
NBIX
$13.8B
| $21.1M | 1.07% |
216,791
+66,927
| +45% | +$6.51M |
|
|
41
BioNTech
BNTX
$24B
| $21M | 1.07% |
+93,839
| New | +$21M |
|
42
Iovance Biotherapeutics
IOVA
$792M
| $20.5M | 1.04% |
788,562
+546,666
| +226% | +$14.2M |
|
43
Allogene Therapeutics
ALLO
$249M
| $20.2M | 1.02% |
773,562
+236,824
| +44% | +$6.18M |
|
44
10x Genomics
TXG
$1.74B
| $20.2M | 1.02% |
102,914
+3,853
| +4% | +$755K |
|
45
Apple
AAPL
$3.41T
| $18.6M | 0.94% |
135,963
+16,333
| +14% | +$2.24M |
|
|
MDRX
46
DELISTED
Veradigm Inc. Common Stock
MDRX
| $18.5M | 0.94% |
997,355
+157,834
| +19% | +$2.92M |
|
|
GTHX
47
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $17.9M | 0.91% |
815,316
+213,725
| +36% | +$4.69M |
|
|
IMGN
48
DELISTED
Immunogen Inc
IMGN
| $17.5M | 0.89% |
2,654,838
+805,066
| +44% | +$5.31M |
|
49
Editas Medicine
EDIT
$222M
| $17.2M | 0.87% |
303,133
+113,939
| +60% | +$6.45M |
|
50
iShares MSCI India ETF
INDA
$9.24B
| $15.5M | 0.79% |
351,200
-50,000
| -12% | -$2.21M |
|